Entrectinib for ROS1 fusion cancers with matching gene test
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer, Immune system & allergy, Skin clinical trials.
This trial studies entrectinib, a targeted pill, in people whose cancer has a specific gene change called ROS1 fusion. It may help by shrinking tumors that depend on this ROS1 gene switch, and the study requires starting with a new tissue sample and treatment monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be ROS1 gene fusion-positive, confirmed by a validated DNA/RNA test on tumor tissue, and it must not be lung cancer (NSCLC).
- You must be able and willing to do a fresh biopsy at the start (and provide blood samples for research).
- You must meet size/body and blood/organ health requirements checked with lab tests (different ranges for adults vs children/teens).
- You need to have safe heart rhythm and heart function: no significant heart failure, recent heart attack/unstable chest pain, major valve problems, or certain QT-interval risks.
- You must be able to safely take tablets/capsules whole and not have bowel/malabsorption problems that would block absorption.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether existing cancer medicines can help people whose tumors have specific “gene changes” (mutations). You may be assigned to a treatment arm that matches your tumor’s gene results after fresh biopsy and blood testing.
This study looks at why the targeted drug entrectinib stops working in some people with ROS1-positive lung cancer. Participants will give blood or tumor samples before and after treatment to help researchers understand resistance.
This trial tests a targeted drug (entrectinib) in very young children (under 3) with a newly diagnosed brain tumor that has a specific genetic change (NTRK or ROS1 fusion). The drug works by blocking signals that help the tumor grow, and is given as the first treatment, before any chemotherapy or radiation.
This study follows people with advanced ROS1-positive non-small cell lung cancer who are taking targeted therapy. It aims to understand how well the treatment works in real life and is for those who haven't had any prior treatment for their lung cancer.
This study looks at how well the drug taletrectinib works for people with a specific type of advanced lung cancer (ROS1-positive NSCLC) whose cancer has gotten worse after treatment with the drug entrectinib. It aims to help doctors understand real-world outcomes for these patients.
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.